噻奈普汀

噻奈普汀是一种非典型抗抑郁药（英语：atypical antidepressant），主要用于重性抑郁疾患的治疗，也可以用来治疗焦虑、气喘和大肠激躁症。 噻奈普汀具有抗抑郁和抗焦虑作用，且镇静性、抗胆碱剂作用和心血管副作用相对较少。人们已发现它是μ-阿片受体（英语：μ-opioid receptor）的非典型激动剂，而对δ-阿片受体（英语：δ-opioid receptor）和κ-阿片受体（英语：κ-opioid receptor）的影响可忽略不计。 噻奈普汀由法国医学研究学会于1960年代发现并获得专利。今天，噻奈普汀在法国获得批准，由Laboratoires Servier（英语：Laboratoires Servier） SA生产和销售。它还在许多其它欧洲国家以商品名Coaxil，以及在亚洲（包括新加坡）和拉丁美洲以商品名Stablon和Tatinol销售，但噻奈普汀不在澳大利亚、加拿大、新西兰、英国或美国销售。 由于其μ-阿片受体（英语：μ-opioid receptor）激动剂效应，远高于治疗剂量的噻奈普汀可以造成类似阿片类药物的欣快感。在这种用法下，噻奈普汀可以成瘾，并且药物戒断反应严重。由于滥用泛滥，新加坡、俄罗斯已加紧对此药物的管制。 Elks J. The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. 14 November 2014: 1195– [2022-03-03]. ISBN 978-1-4757-2085-3. （原始内容存档于2020-08-31）.  Index Nominum 2000: International Drug Directory. Taylor & Francis. 2000: 1024– [2022-03-03]. ISBN 978-3-88763-075-1. （原始内容存档于2020-09-07）.  Tianeptine. [2022-03-03]. （原始内容存档于2012-01-25）.  Tianeptine – AdisInsight. AdisInsight. Springer. [31 January 2016]. （原始内容存档于2022-03-03）.  存档副本. [2022-03-03]. （原始内容存档于2020-12-13）.  Royer RJ, Albin H, Barrucand D, Salvadori-Failler C, Kamoun A. Pharmacokinetic and metabolic parameters of tianeptine in healthy volunteers and in populations with risk factors. Clinical Neuropharmacology. 1988, 11 (Suppl 2): S90–6. PMID 3180120.  Wagstaff AJ, Ormrod D, Spencer CM. Tianeptine: a review of its use in depressive disorders. CNS Drugs. March 2001, 15 (3): 231–59. PMID 11463130. doi:10.2165/00023210-200115030-00006.  Carlhant D, Le Garrec J, Guedes Y, Salvadori C, Mottier D, Riche C. Pharmacokinetics and bioavailability of tianeptine in the elderly. Drug Investigation. September 1990, 2 (3): 167–172. S2CID 56502717. doi:10.1007/BF03259191.  Defrance R, Marey C, Kamoun A. Antidepressant and anxiolytic activities of tianeptine: an overview of clinical trials (PDF). Clinical Neuropharmacology. 1988, 11 (Suppl 2): S74–82. PMID 2902922. （原始内容 (PDF)存档于4 April 2016）.  Kasper S, McEwen BS. Neurobiological and clinical effects of the antidepressant tianeptine. CNS Drugs. 2008, 22 (1): 15–26. PMID 18072812. S2CID 30330824. doi:10.2165/00023210-200822010-00002.  Gassaway MM, Rives ML, Kruegel AC, Javitch JA, Sames D. The atypical antidepressant and neurorestorative agent tianeptine is a μ-opioid receptor agonist. Translational Psychiatry. July 2014, 4 (7): e411. PMC 4119213 . PMID 25026323. doi:10.1038/tp.2014.30.  Berridge KC, Kringelbach ML. Affective neuroscience of pleasure: reward in humans and animals. Psychopharmacology. August 2008, 199 (3): 457–80. PMC 3004012 . PMID 18311558. doi:10.1007/s00213-008-1099-6.  El Zahran T, Schier J, Glidden E, Kieszak S, Law R, Bottei E, et al. Characteristics of Tianeptine Exposures Reported to the National Poison Data System - United States, 2000-2017. MMWR. Morbidity and Mortality Weekly Report. August 2018, 67 (30): 815–818. PMC 6072055 . PMID 30070980. doi:10.15585/mmwr.mm6730a2.  Akiki T. The etiology of depression and the therapeutic implications. Glob. J. Med. Res. [2022-03-03]. ISSN 2249-4618. （原始内容存档于2016-11-03）.  Tianeptine Sodium. Martindale: The Complete Drug Reference (London, UK: Pharmaceutical Press). 5 December 2011 [2 December 2013].  Lauhan R, Hsu A, Alam A, Beizai K. Tianeptine Abuse and Dependence: Case Report and Literature Review. Psychosomatics. November 2018, 59 (6): 547–553. PMID 30149933. S2CID 52099752. doi:10.1016/j.psym.2018.07.006.  Vadachkoria D, Gabunia L, Gambashidze K, Pkhaladze N, Kuridze N. Addictive potential of Tianeptine - the threatening reality. Georgian Medical News. September 2009, (174): 92–4 [2024-07-19]. PMID 19801742. （原始内容存档于2023-12-09）.  World Health Organization. Pharmaceuticals: Restrictions in use and availability, March 2001 (PDF). 2001 [24 July 2008]. （原始内容 (PDF)存档于17 November 2008）.  Ives R. Assessment Mission Report for the SCAD V Programme, Component on Prevention and on Media Work (PDF). 2008 [4 November 2008]. （原始内容 (PDF)存档于1 December 2010）.